CSS
GSK icon

Cubist Systematic Strategies’s GSK GSK Stock Holding History

Cubist Systematic Strategies’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,931
Closed -$983K – 3389
2024
Q1 		$983K Sell
22,931
-32,336
-59% -$1.33M 0.01% 2185
2023
Q4 		$2.05M Buy
55,267
+34,057
+161% +$1.22M 0.01% 1493
2023
Q3 		$769K Buy
+21,210
New +$753K 0.01% 2049
2023
Q2 		– Sell
-183,144
Closed -$6.57M – 3832
2023
Q1 		$6.52M Buy
183,144
+24,578
+16% +$860K 0.04% 741
2022
Q4 		$5.57M Sell
158,566
-818,931
-84% -$27.3M 0.03% 924
2022
Q3 		$28.8M Buy
977,497
+936,455
+2,282% +$35.5M 0.16% 63
2022
Q2 		$2.23M Sell
41,042
-966
-2% -$53.3K 0.01% 1753
2022
Q1 		$2.29M Buy
42,008
+27,092
+182% +$1.47M 0.02% 1374
2021
Q4 		$822K Sell
14,916
-12,690
-46% -$660K 0.01% 2071
2021
Q3 		$1.32M Sell
27,606
-4,932
-15% -$248K 0.02% 1311
2021
Q2 		$1.62M Sell
32,538
-47,091
-59% -$2.26M 0.02% 1235
2021
Q1 		$3.55M Buy
79,629
+17,485
+28% +$794K 0.05% 641
2020
Q4 		$2.86M Buy
62,144
+13,196
+27% +$606K 0.04% 742
2020
Q3 		$2.3M Buy
48,948
+35,117
+254% +$1.76M 0.03% 822
2020
Q2 		$705K Buy
13,831
+7,249
+110% +$372K 0.01% 1395
2020
Q1 		$312K Buy
6,582
+1,616
+33% +$86.2K 0.01% 1497
2019
Q4 		$292K Sell
4,966
-220
-4% -$12.2K 0.01% 1850
2019
Q3 		$277K Sell
5,186
-30,743
-86% -$1.58M 0.01% 1598
2019
Q2 		$1.8M Sell
35,929
-12,746
-26% -$640K 0.03% 729
2019
Q1 		$2.54M Buy
48,675
+42,839
+734% +$2.14M 0.08% 350
2018
Q4 		$279K Sell
5,836
-8,586
-60% -$423K 0.01% 1327
2018
Q3 		$724K Sell
14,422
-26,915
-65% -$1.37M 0.04% 617
2018
Q2 		$2.08M Buy
41,337
+32,814
+385% +$1.65M 0.1% 236
2018
Q1 		$416K Buy
+8,523
New +$397K 0.02% 936
2017
Q4 		– Sell
-29,028
Closed -$1.47M – 1975
2017
Q3 		$1.47M Buy
29,028
+20,228
+230% +$1.03M 0.08% 268
2017
Q2 		$474K Sell
8,800
-5,037
-36% -$269K 0.03% 781
2017
Q1 		$729K Sell
13,837
-14,630
-51% -$742K 0.05% 472
2016
Q4 		$1.37M Buy
28,467
+18,505
+186% +$914K 0.11% 259
2016
Q3 		$537K Sell
9,962
-4,847
-33% -$266K 0.03% 682
2016
Q2 		$802K Buy
14,809
+6,977
+89% +$368K 0.05% 536
2016
Q1 		$397K Sell
7,832
-12,279
-61% -$612K 0.02% 853
2015
Q4 		$1.01M Buy
20,111
+6,935
+53% +$353K 0.06% 465
2015
Q3 		$633K Sell
13,176
-57,711
-81% -$3M 0.03% 804
2015
Q2 		$3.69M Buy
70,887
+64,577
+1,023% +$3.64M 0.18% 110
2015
Q1 		$364K Sell
6,310
-5,708
-47% -$327K 0.02% 1140
2014
Q4 		$642K Buy
12,018
+2,315
+24% +$130K 0.03% 738
2014
Q3 		$558K Buy
9,703
+4,244
+78% +$260K 0.03% 763
2014
Q2 		$365K Buy
+5,459
New +$370K 0.02% 876

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Cubist Systematic Strategies's GSK Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of GSK (GSK) in Q2 2024, closing a stake of 22,931 shares — an estimated $983K sold.

Cubist Systematic Strategies first reported a position in GSK in Q2 2014 and held it in 38 quarters. The position peaked at $28.8M in Q3 2022. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 22,931 GSK shares in Q2 2024, an estimated $983K.
  • Cubist Systematic Strategies first reported a position in GSK in Q2 2014 and held it in 38 quarters.
  • Cubist Systematic Strategies's GSK position peaked at $28.8M in Q3 2022.
  • 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.